Anacetrapib is a novel cholesteryl ester transfer protein inhibitor being developed for the treatment of primary hypercholesterolemia and mixed dyslipidemia. The absorption, distribution, metabolism, and excretion of anacetrapib were investigated in an openlabel study in which six healthy male subjects received a single oral dose of 150 mg and 165 Ci of [ 14 C]anacetrapib. Plasma, urine, and fecal samples were collected at predetermined times for up to 14 days postdose and were analyzed for total radioactivity, the parent compound, and metabolites. The majority of the administered radioactivity (87%) was eliminated by fecal excretion, with negligible amounts present in urine (0.1%). The peak level of radioactivity in plasma (ϳ2 M equivalents of [ 14 C]anacetrapib) was achieved ϳ4 h postdose. The parent compound was the major radioactive component (79-94% of total radioactivity) in both plasma and feces. Three oxidative metabolites, M1, M2, and M3, were detected in plasma and feces and were identified as the O-demethylated species (M1) and two secondary hydroxylated derivatives of M1 (M2 and M3). Each metabolite was detected at low levels, representing <14% of the radioactivity in plasma or fecal samples. In vitro data indicated that anacetrapib is metabolized mainly by CYP3A4 to form M1, M2, and M3. Overall, these data, along with those from other preclinical and clinical studies, indicate that anacetrapib probably exhibits a low-to-moderate degree of oral absorption in humans and the absorbed fraction of the dose is eliminated largely via CYP3A4-catalyzed oxidative metabolism, followed by excretion of metabolites by the biliary-fecal route.
As described in the companion article, anacetrapib [4S, phenyl]-3-{[4Ј-fluoro-2Ј-methoxy-5Ј-(propan-2-yl)-4-(trifluoromethyl)[1,1Ј-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one; Merck, Whitehouse Station, NJ) is a potent and selective inhibitor of CETP and is undergoing development as an oral drug for the treatment of primary hypercholesterolemia and mixed hyperlipidemia. In phase I and II clinical trials, anacetrapib has shown impressive effects on the plasma lipid profile including increases in HDL cholesterol levels of ϳ130% and reduction in LDL cholesterol levels by ϳ40%, with no associated major adverse events (Krishna et al., 2007 (Krishna et al., , 2008 Bloomfield et al., 2009) . Furthermore, as opposed to torcetrapib (Pfizer Inc., New York, NY), anacetrapib showed no treatment-related effect on blood pressure in a 24-h ambulatory blood pressure clinical trial (Krishna et al., 2007) . These preliminary pharmacodynamic and safety observations with anacetrapib provide support for further evaluation of the efficacy of this drug in cardiovascular disease upon long-term treatment.
The objective of this study was to investigate the routes of elimination and the excretion mass balance after a single oral dose of [ 14 C]anacetrapib in humans. Major metabolites of anacetrapib were identified in humans and compared with those detected in preclinical toxicology species (as described in the companion article) to ascertain adequacy of the preclinical safety assessment evaluation of this drug in terms of metabolite qualification.
Medicinal Chemistry at MRL. The Imwitor 742-Tween 80 formulation and liquid-filled capsules were prepared by Pharmaceutical Research and Development at MRL (West Point, PA). Insect cell microsomes expressing individual human cytochrome P450 (P450) enzymes were prepared at MRL via baculovirus expression. Monoclonal inhibitory antibody against CYP3A4 was generated in mice at MRL via immunization with recombinant CYP3A4. Liver microsomes from humans were prepared at MRL (Rahway, NJ). All other reagents were of an appropriate purity and were obtained from commercial sources.
Clinical Study Design. The protocol was approved by the local institutional review board (Covance Clinical Research, Evansville, IN) , and study participants provided written informed consent before enrollment. The study was conducted in accordance with the guidelines on good clinical practice and with ethical standards for human experimentation established by the Declaration of Helsinki. In an open-label study, six healthy male subjects (18 -45 years of age) were admitted to the clinical research unit the evening before dosing and remained in the unit until completion of all laboratory collections for the whole duration of the study. All subjects received a single oral dose of 150 mg of [ 14 C]anacetrapib, administered as three liquid-filled capsules each containing 50 mg of anacetrapib and a total of 165 Ci of radioactivity in an Imwitor 742-Tween 80 (1:1, w/w) formulation. At 30 min before drug administration, all subjects consumed a standard low-fat breakfast. Anacetrapib doses were administered to all subjects with 240 ml of water, and the subjects remained semirecumbent for 4 h postdose. Blood samples (15 ml each) were collected in heparinized tubes at 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 36, 48, 60, 72, 96, 120, 144, 168, 192, 216, 240, 264, 288, 312 , and 336 h postdose. Urine and feces were collected daily for 14 days. Plasma samples were stored at Ϫ70°C, and urine and fecal samples were stored at Ϫ20°C before and after analysis. The safety and tolerability of anacetrapib were assessed by a clinical evaluation of adverse experiences and inspection of other safety parameters including vital signs, physical examination, laboratory safety assessment, and electrocardiograms at selected intervals.
Determination of Radioactivity in Plasma, Urine, and Fecal Samples. The total radioactivity in all plasma samples was determined by liquid scintillation counting (Packard Tri-Carb 3170TR/SL; PerkinElmer Life and Analytical Sciences, Waltham, MA). After vortexing of each plasma sample at 2600 rpm for 30 s, triplicate aliquots of 0.5 ml of plasma were mixed with 6 ml of Pico-Fluor 30 scintillation cocktail (PerkinElmer Life and Analytical Sciences) and counted for 5 min. Scintillation counter data were automatically corrected for counting efficiency using an external standardization technique, and an instrument-stored quench curve was generated from a series of sealed quench standards. The total radioactivity and percent dose excreted in urine and feces were determined by Covance Laboratories Inc. (Madison, WI) .
Metabolite Profiling for Plasma, Urine, and Fecal Samples. Plasma and fecal samples were pooled and extracted for metabolite profiling, but the radioactivity in urine was too low for any meaningful metabolite profiling. Plasma samples taken at 3, 8, 20, and 36 h postdose were pooled based on equal plasma volume from each individual sample. A preweighed amount of ethanol-water (1:4, v/v) was added to each fecal sample to form a ϳ20% fecal homogenate. Fecal samples collected from 0 to 168 h postdose for each subject were pooled using 1% by weight of samples collected at individual time points. In addition, a final pool of all six subjects was prepared using an equal weight of each individual's pooled homogenized fecal sample above.
The resulting pooled plasma and fecal homogenate samples were extracted as follows. The samples were thoroughly mixed with 2 volume equivalents of acetonitrile via sonication (10 min) and vortex (10 min), and then centrifuged at 3000 rpm for 10 min. The supernatants were transferred to a new container, and the pellets were resuspended in 0.5 ml of water via vortexing (10 min) and then thoroughly mixed with 2 ml of acetonitrile via sonication (10 min) and vortexing (10 min). The mixed samples were centrifuged at 3000 rpm for 10 min. All supernatants were evaporated to dryness under a stream of nitrogen at room temperature. The dried extracts were sequentially dissolved in 100 to 200 l of water, methanol, and acetonitrile via vortexing. The resulting extracts were analyzed by LC-MS coupled with radiometric detection after centrifugation to separate the particulate material. The extraction recovery was determined by comparing the radioactivity of the combined extracts (ϳ500 l) and the original plasma or fecal homogenate samples. The extraction recovery was ϳ80% for the pooled fecal sample, ϳ95% for the 3-and 8-h plasma samples, and ϳ75% for the 20-and 36-h plasma samples.
Qualitative LC-MS/MS and Radiometric Analysis. The LC-MS system consisted of a Shimadzu SIL-10ADvp autosampler, a Shimadzu SCL10Avp system controller, two Shimadzu LC-10ADvp pumps (Shimadzu, Columbia, MD), a Packard flow scintillation analyzer (500TR series; PerkinElmer Life and Analytical Sciences), and a ThermoFinnigan LTQ XL Orbitrap or LXQ ion trap mass spectrometer (Thermo Fisher Scientific, Waltham, MA). The mass spectrometers were operated in positive (anacetrapib) or negative (metabolites) ion detection mode using electrospray ionization, and data were acquired using Xcalibur software (version 2; Thermo Fisher Scientific). The MS n spectra were recorded in a data-and list-dependent mode. A Zorbax RX-C8 HPLC column (4.6 ϫ 250 mm, 5 m; Waters, Milford, MA) was used for chromatographic separation. The mobile phases A and B were 5% aqueous acetonitrile (v/v) and 95% aqueous acetonitrile (v/v), respectively, both containing 0.1% formic acid and 1 mM ammonium acetate. The gradient elution started at 5% B for the first 3 min and increased linearly to 35% B in 2 min, to 42% B in 43 min, to 75% B in 17 min, and finally to 100% B in 5 min where it was held for an additional 5 min. The flow rate was 1.5 ml/min, and the eluate was diverted at a 5:1 ratio to the Packard flow scintillation analyzer and the LXQ mass spectrometer, respectively. Scintillation cocktail (Ultima Flo-M; Packard Bioscience B.V., Gronigen, The Netherlands) was pumped at a rate of 3.8 ml/min to the radiometric detector.
The LC fraction collector coupled system consisted of the same Shimadzu LC system used above and a Gilson fraction collector Gilson, Inc., Middleton, WI) . Identical LC conditions were used as describe above. Fractions were collected every 0.5 min into 7-ml scintillation vials for 80 min (160 fractions/run), and Pico-Fluor 30 (6 ml) was added to each collection for radioactivity analysis using a Packard Tri-Carb 3170TR/SL liquid scintillation counter. Self-normalization and calibration samples were run before each sample analysis. The column recovery was determined by comparing the total radioactivity from all collected fractions with that in the injected sample. All runs demonstrated a column elution recovery of 93 to 100% relative to the injected radioactivity.
Because metabolites of anacetrapib were only detected in low nanomolar concentrations in human biological samples, sufficient amounts could not be obtained for NMR analysis. Thus, to provide unequivocal structural assignment, high-resolution accurate mass CID spectra of anacetrapib metabolites from human biological samples were also obtained using a Thermo LTQ XL Orbitrap Hybrid Fourier transform mass spectrometer (with the same LC conditions as described above) and compared with those of synthetic standards in addition to comparison of their LC retention time and nominal mass CID spectra. The mass spectrometer was operated in positive (anacetrapib) or negative (metabolites) ion detection mode with electrospray ionization using Xcalibur software (version 2). Accurate masses of the analyte molecular ions and their CID fragment ions were recorded by Fourier transform mass spectrometry scans with a resolution of 60,000 and a mass accuracy of 5 ppm over a mass range of 100 to 1000 Da. For comparison of the mass spectra, synthetic metabolite standards were directly infused at a concentration of 10 M and a flow rate of 10 l/min, and high-resolution mass spectra of the standards were recorded with the same scan parameters.
Quantitative LC-MS/MS Analysis. The plasma concentration of anacetrapib in humans was determined by LC-MS/MS. The LC-MS/MS system consisted of a PerkinElmer biocompatible binary pump 250, a PerkinElmer 200 autoinjector (PerkinElmer Life and Analytical Sciences), and a Sciex API 3000 mass spectrometer (Applied Biosystems, Foster City, CA) equipped with a TurboIonSpray interface. Aliquots of plasma samples (0.25 ml), to which internal standard ([methyl-O-13 CD 3 ]anacetrapib) was added, were extracted using a liquid-liquid extraction method with isopropyl alcohol-hexane (1:4, v/v; 1.2 ml). Chromatography was performed on a Phenomenex Synergi Polar-RP column (50 ϫ 2 mm, 4 m) with 0.1% formic acid in a 70% acetonitrile aqueous mobile phase at a flow rate of 0.4 ml/min. The MS analysis was performed in positive ion mode using multiple reaction monitoring; the precursor-to-product ion transitions were m/z 638 3 283 and m/zPharmacokinetic Calculations. Plasma concentrations of anacetrapib and radioactivity were converted into molar and molar equivalent units, respectively, using the molecular weight of 637.5 before pharmacokinetic analysis. Maximal observed plasma concentrations (C max ) and time of maximal plasma concentrations (T max ) of anacetrapib and radioactivity were obtained from the plasma concentration versus time profiles. The areas under the plasma concentration versus time curve to 96 h, which was the last time point at which the radioactivity was above the limit of quantitation, for anacetrapib and radioactivity were calculated using the linear trapezoidal method for ascending concentrations and the log trapezoidal method for descending concentrations. WinNonlin 4.1 (Pharsight, Mountain View, CA) was used for pharmacokinetic calculations.
Identification of P450 Enzymes Involved in the Metabolism of Anacetrapib. [
14 C]Anacetrapib (10 M) was incubated with individually expressed recombinant P450 enzymes (200 pmol/ml CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4 suspension in 0.1 M phosphate buffer containing 1 mM EDTA at pH 7.4) in the presence of 5 mM NADPH. After incubation at 37°C for 60 min, the reactions were terminated by addition of 10 l of 10% aqueous TFA. For investigating the effect of CYP3A4 inhibition on anacetrapib metabolism in human liver microsomes, [
14 C]anacetrapib (10 M) was incubated in human liver microsomal suspensions (1 mg/ml) in the presence of 5 mM NADPH and ketoconazole (0, 1, or 10 M) in 0.1 M phosphate buffer (pH 7.4) containing 1 mM EDTA. After incubation at 37°C for 60 min, the metabolic reaction was terminated by adding 10 l of 10% aqueous TFA. The effect of anti-CYP3A4 monoclonal antibody was determined by preincubating human liver microsomes (1 mg/ml) with the antibody (0, 0.2, or 2 mg/ml) in 0.1 M phosphate buffer (pH 7.4) at room temperature for 30 min, followed by the addition of [ 14 C]anacetrapib (10 M) and 5 mM NADPH. After incubation at 37°C for 60 min, the metabolic reaction was terminated by adding 10 l of 10% aqueous TFA.
All samples from in vitro incubations were extracted by Oasis HLB extraction cartridges (0.2 g; Waters), and analytes were eluted from cartridges with 2 ml of methanol. The eluate was evaporated to dryness at room temperature under a gentle stream of nitrogen gas. The residue was reconstituted in 0.3 ml of 50% aqueous acetonitrile (v/v), 50 l of which was injected onto a Synergi Hydro-RP HPLC column and analyzed by LC-MS and radiometric detection for metabolites formation as described under Qualitative LC-MS/MS and Radiometric Analysis.
In Vitro Reversible Plasma Protein Binding. [ 14 C]Anacetrapib in ethanol (2.5 l) was added to human plasma (497.5 l) to achieve final concentrations of 1, 5, and 20 M. Equilibrium dialysis of plasma samples was performed for 6 h against isotonic phosphate buffer (pH 7.4, 1.8 g/l KH 2 PO 4 , 7.6 g/l Na 2 HPO 4 , and 3.9 g/l NaCl) at 37°C in 1-ml acrylic dialysis cells (Scienceware; Bel-Art Products, Pequannock, NJ). The plasma and buffer were separated by a membrane (Sigma-Aldrich, St. Louis, MO) that had a molecular mass cutoff of 12.4 kDa. Aliquots (100 l) of the plasma and phosphate buffer were measured for radioactivity using a liquid scintillation counter [Beckman LS6500 (Beckman Coulter, Inc., Fullerton, CA) or Packard 1900TR]. Estimation of the unbound fraction of anacetrapib was based on the ratio of radioactivity in the buffer over that in the plasma samples. The limit of quantification using liquid scintillation counting (ϳ2-fold above background radioactivity) in this assay was ϳ5 nM.
In Vitro Blood/Plasma Partition Ratio. [ 14 C]Anacetrapib in ethanol (2.5 l) was added to human blood and plasma (497.5 l each) to achieve final concentrations of 1, 5, and 20 M. The resulting blood and plasma samples (0.5 ml each) were incubated at 37°C for 30 min. Blood samples then were subjected to centrifugation at 3000 rpm (Beckman GS6R) for 10 min to obtain plasma. Aliquots (0.1 ml) of plasma samples were measured for radioactivity by a scintillation counter (Beckman LS6500). The blood/plasma partition ratio was estimated via comparison of the radioactivity in plasma prepared from the treated blood samples with that in control plasma.
Results
Safety and Tolerability. Anacetrapib was generally well tolerated in study volunteers with no meaningful changes in vital signs, electrocardiogram, and routine laboratory safety assessment tests.
There were no other clinically meaningful adverse events observed in any subject participating in this study.
Excretion of Radioactivity. The excretion of radioactivity in human urine and feces after a single 150 mg (165 Ci) oral dose of [
14 C]anacetrapib is summarized in Table 1 . The results indicated that the majority of the radioactivity was excreted in feces, with an average recovery value of 87% of the administered dose within 14 days (individual recovery ranged from 67 to 103%). The average extent of urinary excretion of radioactivity over a 14-day period was ϳ0.1% of the administered dose. The average total recovery of radioactivity in excreta was 87%. A large portion of the radioactivity (76%) was excreted within 3 days postdose, and the cumulative radioactivity recovery versus time profile reached a plateau around the 7th day. The recoveries of radioactivity in feces were similar in five of the six subjects, but the radioactivity recovery in one subject was lower (67%) compared with that in the other subjects (85-103%). Because no noncompliance was reported for this subject, the data from this subject were included in calculation of the mean values. shown in Fig. 1 , and pharmacokinetic parameters for all subjects are summarized in Table 2 . After oral administration, anacetrapib and total radioactivity concentrations reached a maximum (C max ) in plasma between 3 and 5 h (T max ). Plasma radioactivity levels fell below the limit of quantitation (ϳ100 nM Eq) after 96 h postdose.
The area under the plasma concentration versus time curve (AUC) ranged from 20 to 35 M ⅐ h for total radioactivity and from 9 to 22 M ⅐ h for anacetrapib. The anacetrapib/radioactivity ratios for AUC and C max were 0.52 and 0.84, respectively. Likewise, contribution of anacetrapib to total radioactivity in plasma ranged from 79 to 94% based on HPLC radioactivity profiles at 3, 8, 20, and 36 h postdose (Table 3) . Identification of Metabolites. The structures of anacetrapib metabolites identified in human samples after oral dosing of 150 mg of anacetrapib are shown in Figs. 2 to 6 . The metabolite identification was performed by comparison of the LC retention times and CID spectra (both nominal mass and high resolution) of metabolites in biological samples with those of the available synthetic standards of M1, M2, and M3. The nominal mass spectral data for these metabolites were discussed in the companion article on the metabolism of anacetrapib in rats and monkeys (Tan et al., 2010) , and only high-resolution mass spectral data are presented in this manuscript. Figures 3 to 6 depict the high-resolution CID fragmentation spectra for anacetrapib and M1, M2, and M3 metabolites, along with the proposed structures of various fragment ions and their theoretical accurate masses. Table 4 presents the elemental composition of the molecular and fragments ions of anacetrapib and its metabolites derived from their measured accurate masses and the associated deviations (in parts per million) relative to the theoretical masses of these ions; all of these deviations were Ͻ5 ppm, which lends confidence to the assigned structures of fragment ions and actual metabolites. Anacetrapib could only be detected in positive ion detection mode and exhibited a molecular ion [M ϩ H] ϩ at m/z 638.1755 ( Fig. 3 ; Table 4 ). Two fragment ions at m/z 314.0601 and 325.1200 were attributed to cleavage of the bond between the nitrogen of oxazolidinone and the methylene linkage to the biphenyl moiety of anacetrapib. The mass of the fragment ion at m/z 283.0731 is consistent with an elemental composition of [C 15 H 11 OF 4 ] ϩ , suggesting that it was derived from the 4Ј-fluoro-5Ј-isopropyl-2Ј-methoxy-4-(trifluoromethyl)biphenyl moiety of the molecule after loss of elements of isopropylene (C 3 H 6 ). In contrast to the parent, metabolites M1, M2, and M3 could only be a AUC from 0 to 96 h was calculated with a linear trapezoid method for ascending concentrations and the log trapezoidal method for descending concentrations. Plasma radioactivity data obtained after 96 h were below the limit of quantitation (ϳ100 nM Eq) and were to be interpreted with caution. (Fig. 4) , the prominent fragment ions at m/z 312 and 578 were attributed to cleavage of the C-N bond between the methylene linkage between the oxazolidinone and biphenyl moieties and to the loss of elements of carbon dioxide, respectively. M2 displayed a molecular ion [M Ϫ H] Ϫ ion at m/z 638.1392, which represents a net addition of ϳ2 Da to anacetrapib. From analysis of the propyl moiety of anacetrapib (Fig. 6 ). As depicted in Fig. 6 , the fragment ion at m/z 536.1068 is consistent with the loss of the hydroxy-isopropyl moiety (C 3 H 6 O) from the core structure of M3 (from fragment ion at m/z 594.1496), indicating that hydroxylation had occurred at the isopropyl moiety. We believe that a comparison of the LC retention time and high-resolution CID spectra of M1, M2, and M3 with those of the synthetic standards provides unequivocal structural identification of these metabolites of anacetrapib in human plasma and other matrices. Metabolite Profiles in Plasma, Urine, and Fecal Samples. Radiochromatograms of plasma pooled across all subjects at 3, 8, 20, and 36 h postdose are shown in Fig. 7 . Anacetrapib and the metabolites detected, namely M1, M2, and M3, were designated according to their MS/MS characteristics and relative LC radiochromatogram retention times. Radioactivity in pooled plasma comprised primarily anacetrapib at all time points analyzed, which accounted for 79 to 94% of the total radioactivity in each sample. M1, M2, and M3 also were detectable in these plasma samples. M2 was the most abundant metabolite and accounted for 4 to 14% of the total radioactivity in plasma samples. M1 (ϳ1%) and M3 (1-7%) were minor circulating metabolites in these plasma samples.
The radiochromatogram of a pooled human fecal sample collected from 0 to 168 h postdose is presented in Fig. 8 . Fecal samples collected between 168 and 336 h postdose were not analyzed owing to low levels of radioactivity. Anacetrapib was the major radioactive component in feces and comprised 91% of the total fecal radioactivity. M1, M2, and M3 metabolites were detected in feces and represented 1, 4, and 3%, respectively, of the total fecal radioactivity. Urine samples were not analyzed because of low levels of radioactivity.
Identification of P450 Enzymes Involved in the Metabolism of Anacetrapib. In vitro incubations of 10 M [
14 C]anacetrapib in NADPH-enriched recombinant human P450 enzymes indicated that anacetrapib metabolism occurred only in the CYP3A4 incubation (Fig. 9) . Three oxidative metabolites, namely M1, M2, and M3, were detected in in vitro incubations of 10 M [ 14 C]anacetrapib in NADPH-enriched human liver microsomes and recombinant CYP3A4; no metabolites were observed with any of the other recombinant P450s. Metabolism of anacetrapib to M1, M2, and M3 in human liver microsomes was completely inhibited by ketoconazole and an inhibitory anti-CYP3A4 antibody. Based on these in vitro data, it seems that anacetrapib is mainly metabolized by CYP3A4 to form M1, M2, and M3.
In Vitro Reversible Plasma Protein Binding and Blood/ Plasma Partition Ratio. The unbound fractions of anacetrapib in human plasma and the blood/plasma partition ratio of anacetrapib were Ͻ0.5 and 0.7, respectively, over a concentration range of 1 to 20 M.
Discussion
In this study, we characterized the routes of elimination, metabolism, and excretion mass balance of [ 14 C]anacetrapib after a single oral dose in humans. A radioactivity dose of 165 Ci of [ 14 C]anacetrapib was selected for this study based on radioactivity dosimetry estimations from mass balance and tissue distribution of [ 14 C]anacetrapib in rats. An anacetrapib dose of 150 mg was administered in this study because this is approximately at the higher end of the anticipated clinical dose range at which optimal reduction of LDL cholesterol and elevation of HDL cholesterol is expected (Krishna et al., 2008) .
In the current study, the majority of the administered radioactivity was excreted within 3 days postdose, and the total recovery of radioactivity 2 weeks postdose was 87%, which is within the range of normal excretion recovery values observed for many drugs (Roffey et al., 2007) . Anacetrapib was eliminated primarily via the fecal route (87% of dose), and urinary elimination accounted for only ϳ0.1% of the dose. These results are consistent with data from preclinical toxicology species, in which anacetrapib was eliminated mainly in feces also (Tan et al., 2010) . Although the absolute oral bioavailability of anacetrapib is not known, the bioavailability (and oral absorption) of anacetrapib in the preclinical safety species (rats and monkeys) ranged from 13 to 38% at oral doses of 1 to 5 mg/kg (Tan et al., 2010) . Hence, it can be concluded that anacetrapib probably has low-to-moderate oral bioavailability/absorption in humans and a significant portion of the radioactivity in feces can be attributed to nonabsorbed anacetrapib. Assuming that the majority of absorbed anacetrapib is cleared via metabolism (see below) and parent drug in feces largely represents unabsorbed material, it can be estimated that the fraction absorbed is at most ϳ20% (87% of dose recovered in feces, 91% of which is unabsorbed parent drug). Despite the limited extent of absorption after oral dosing, anacetrapib appears to have very favorable pharmacokinetic properties in that it achieves adequate systemic exposures at clinically reasonable doses (Krishna et al., 2008) . The plasma pharmacokinetic parameters, including AUC, C max , and T max , obtained in this study were consistent with prior observations dmd.aspetjournals.org in phase I and II clinical studies (Krishna et al., 2007 (Krishna et al., , 2008 (Krishna et al., , 2009 ). In addition, it has been demonstrated previously that within the relevant dose range, anacetrapib is capable of effectively decreasing plasma LDL (ϳ40%) and raising HDL (ϳ130%) levels (Krishna et al., 2007) . Because anancetrapib has a high affinity for plasma CETP (Tan et al., 2010) , this protein, possibly along with others in plasma, contributes to its high observed plasma protein binding (Ͼ99.5%).
After an oral dose of [ 14 C]anacetrapib, the parent compound was the major drug-related component (79 -94%) in human plasma and feces, whereas radioactivity in urine was too low for any meaningful metabolite profiling. LC-MS analysis of the plasma and fecal samples in conjunction with radiochromatography revealed the presence of O-demethylated (M1) and hydroxylated metabolites (M2 and M3). Each metabolite, M1, M2, and M3, was detected at low nanomolar levels representing Յ4 and Յ14% of the radioactivity in fecal and plasma radiochromatograms, respectively. Because these metabolites have Ͼ14-fold less potent in vitro pharmacological activity than anacetrapib (P. J. Sinclair, unpublished data), it is unlikely that they would contribute to the overall pharmacological effect to any significant extent. These metabolites also were detected in rats and rhesus monkeys, the two species used in the preclinical toxicological evaluation of anacetrapib. Thus, all human metabolites of anacetrapib are adequately qualified in preclinical toxicology species. Furthermore, it appears that in rats and monkeys, the fraction of the orally administered dose of anacetrapib that is absorbed into the systemic circulation is eliminated largely via oxidative metabolism and excretion of oxidative metabolites (either as such or as glucuronide conjugates) into bile (Tan et al., 2010) . Although bile samples were not accessible from humans, it can be speculated that the absorbed fraction of orally administered anacetrapib in humans undergoes a similar fate as in animals in terms of routes of elimination; i.e., oxidative metabolism is the major route of clearance of anacetrapib from the systemic circulation. This finding is further substantiated by the fact that a clinical drug-drug interaction study of anacetrapib (25 mg) with the potent CYP3A4 inhibitor, ketoconazole (400 mg q.d.), demonstrated a 4.6-fold increase in anacetrapib exposure (Krishna et al., 2009) , suggesting that oxidative metabolism via CYP3A4 is a significant clearance pathway for the systemically absorbed fraction of this drug.
Data on animal and human disposition and metabolism of torcetrapib, another CETP inhibitor that progressed into late clinical development before it was discontinued as a result of unfavorable cardiovascular outcomes, have also been published recently Prakash et al., 2008) . A comparison of the absorption, distribution, metabolism, and excretion profile for anacetrapib and torcetrapib reveals significant differences between the disposition and metabolism of these two CETP inhibitors. Although the plasma kinetics of both compounds exhibit long terminal half-lives of Ͼ100 h, the two drugs are strikingly different in their routes of elimination and their metabolic profiles. The findings of this study indicate that anacetrapib is primarily excreted in feces as unchanged drug in humans, with minimal excretion of the radioactive dose in urine. Moreover, data from bile duct-cannulated rats and monkeys (Tan et al., 2010) have confirmed that in preclinical species, hepatic metabolism and biliary, but not renal, excretion of metabolites constitutes an important pathway of elimination for anacetrapib. In comparison, the elimination of torcetrapib is governed mainly through urinary excretion of its metabolites. This difference in routes of excretion of drug-related material between the two agents appears related to differences in their metabolic pathways. Anacetrapib undergoes relatively simple metabolism in humans to only three oxidative metabolites via CYP3A4-mediated O-demethylation and hydroxylation on the biphenyl and isopropyl moieties as shown in Fig. 2 . Furthermore, the plasma radioactivity profiles after [
14 C]anacetrapib administration are dominated by the parent drug (50 -60% of total drug-related material) and only small amounts of the above oxidative metabolites circulate in human plasma. In contrast, torcetrapib exhibits a complex metabolic fate with as many as 15 or more primary and secondary metabolites identified in humans. A key feature of the metabolism of torcetrapib appears to be related to oxidative cleavage in its core structure between the bistrifluoromethylbenzyl and dihydroquinoline moieties, which results in the formation of low-molecularweight metabolites including quinaldic acid and bistrifluoromethylbenzoic acid from the two halves of the parent compound. These low-molecular-weight metabolites are more suited to excretion via the renal pathway and seem to account for the observed differences in routes of excretion of drug-related material between torcetrapib and anacetrapib. In contrast, the overall structure of anacetrapib seems to stay largely intact after metabolism, and the metabolites have a relatively high molecular mass (Ͼ600 Da), which is more suited for excretion via the biliary/fecal pathway. Furthermore, in contrast to anacetrapib, the plasma radioactivity profile after [ 14 C]torcetrapib administration is dominated by metabolites, and torcetrapib itself accounts only for ϳ7% of the circulating radioactivity. In particular, plasma exposures (AUC) of the lowmolecular-weight metabolites of torcetrapib including quinaldic acid and bistrifluoromethylbenzoic acid were ϳ3-and ϳ139-fold greater relative to that of the parent drug, suggesting that these low-molecular-weight metabolites either have a small volume of distribution and/or slower clearance relative to the parent torcetrapib .
In conclusion, disposition and metabolism of [ 14 C]anacetrapib were investigated in healthy human volunteers after a single oral dose. The majority of the administered radioactivity was excreted via the fecal route and was composed largely of the parent drug along with small amounts of three oxidative metabolites (M1, M2, and M3). The metabolic pathways identified included CYP3A4-catalyzed O-demethylation to M1, which was probably further hydroxylated at the biphenyl and isopropyl moieties to form M2 and M3, respectively. Collective data on the disposition of anacetrapib in rats, monkeys, and humans indicates that anacetrapib probably exhibits a low-to-moderate degree of oral absorption across all species and a major pathway of elimination of the absorbed drug is through oxidative metabolism followed by excretion of metabolites (and their conjugates) via the biliary/fecal route.
